Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.36 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.36 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.36 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.36 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979027 | 0.93 | TLR7 (0.48) | TLR7TLR8ALDH1A1SMN1; SMN2 | |
| SCHEMBL2513263 | 0.92 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL9979161 | 0.90 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL9979077 | 0.89 | MTNR1A (0.40) | TLR7TLR8ALDH1A1 | |
| SCHEMBL9979143 | 0.88 | TLR7 (0.38) | TLR7TLR8KDM4EALDH1A1 | |
| SCHEMBL11917315 | 0.88 | TLR7 (0.40) | TLR7TLR8 | |
| SCHEMBL9979057 | 0.88 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL2513545 | 0.88 | TLR7 (0.40) | TLR7TLR8 | |
| SCHEMBL19917075 | 0.88 | TLR7 (0.37) | TLR7TLR8 | |
| Hydrochloric Acid SCHEMBL21074149 | 0.87 | TLR7 (0.37) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350034-B2 | Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-08 | — | — | US | claimed |
| US-20110293654-A1 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMANY | 2011-12-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110293654-A1 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IL4, IFNAR1 | TLR7 171/4885TLR8 359/4885KDM4E 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.